Skip to main content
    I

    Intuitive Surgical Inc (ISRG)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $437.75
    -5.84 (-1.32%)

    Market Cap: $153.77B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Intuitive Surgical Inc (ISRG) Earnings: Report Dates and Results

    Updated Oct 20, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Intuitive Surgical (ISRG) is expected to report earnings on Jan 20, 2027. In the quarter ended Sep 30, 2026, Intuitive Surgical reported EPS of $3.00, above the $2.13 estimate. It beat the EPS estimate in each of the last 15 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    90%(36/40)
    Avg Surprise
    +14.95%
    Streak
    15 Q

    Upcoming Estimates

    Reports Jan 20, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$3.01
    Range$2.79 - $3.19
    30 analysts
    Revenue Consensus
    $3.30B
    Range$3.06B - $3.46B
    30 analysts
    Reports Apr 19, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$2.85
    Range$2.62 - $3.01
    21 analysts
    EPS Revisions
    14
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$2.80+2.0%
    60d ago$2.80+2.0%
    30d ago$2.80+1.9%
    7d ago$2.850.0%
    Current$2.85
    Revenue Consensus
    $3.12B
    Range$2.96B - $3.25B
    18 analysts

    Next Report

    ISRG has an expected report date of Jan 20, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 19.0% above the $2.53 reported for the quarter ended Dec 31, 2025.

    ISRG Earnings Call

    The latest ISRG earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, ISRG beat 36 and missed 4. Revenue for the quarter ended Sep 30, 2026 was $3.05B, up 21.5% from $2.51B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$3.00$2.13N/A+40.85%Beat+25.0%241 up, 0 downOct 20, 2026$3.05B
    Jun 30, 2026$2.80$2.02N/A+38.61%Beat+27.9%232 up, 0 downJul 16, 2026$2.89B
    Mar 31, 2026$2.50$2.11$2.03 - $2.29+18.48%Beat+38.1%241 up, 0 downApr 21, 2026$2.77B
    Dec 31, 2025$2.53$2.27$2.13 - $2.45+11.45%Beat+14.5%265 up, 0 downJan 22, 2026$2.87B
    Sep 30, 2025$2.40$1.99$1.85 - $2.11+20.60%Beat+30.4%240 up, 1 downOct 21, 2025$2.51B
    Jun 30, 2025$2.19$1.92$1.87 - $2.12+14.06%Beat+23.0%251 up, 0 downJul 22, 2025$2.44B
    Mar 31, 2025$1.81$1.73$1.58 - $1.87+4.62%Beat+20.7%242 up, 3 downApr 22, 2025$2.25B
    Dec 31, 2024$2.21$1.79$1.64 - $1.98+23.46%Beat+38.1%256 up, 0 downJan 23, 2025$2.41B
    Sep 30, 2024$1.84$1.64$1.53 - $1.72+12.20%Beat+26.0%230 up, 1 downOct 17, 2024$2.04B
    Jun 30, 2024$1.78$1.54$1.48 - $1.61+15.58%Beat+25.4%232 up, 0 downJul 18, 2024$2.01B
    Mar 31, 2024$1.50$1.42$1.30 - $1.54+5.63%Beat+22.0%200 up, 0 downApr 18, 2024$1.89B
    Dec 31, 2023$1.60$1.49$1.40 - $1.56+7.38%Beat+30.1%226 up, 0 downJan 23, 2024$1.93B
    Sep 30, 2023$1.46$1.42$1.34 - $1.50+2.82%Beat+22.7%220 up, 3 downOct 19, 2023$1.74B
    Jun 30, 2023$1.42$1.33$1.23 - $1.37+6.77%Beat+24.6%210 up, 0 downJul 20, 2023$1.76B
    Mar 31, 2023$1.23$1.20$1.15 - $1.25+2.50%Beat+8.8%182 up, 1 downApr 18, 2023$1.70B
    Dec 31, 2022$1.23$1.25$1.14 - $1.32-1.60%Miss-5.4%182 up, 1 downJan 24, 2023$1.66B
    Sep 30, 2022$1.19$1.12$1.06 - $1.22+6.25%Beat0.0%192 up, 1 downOct 18, 2022$1.56B
    Jun 30, 2022$1.14$1.20$1.09 - $1.27-5.00%Miss-13.0%161 up, 0 downJul 21, 2022$1.52B
    Mar 31, 2022$1.13$1.08$1.02 - $1.13+4.63%Beat-3.4%170 up, 1 downApr 21, 2022$1.49B
    Dec 31, 2021$1.30$1.28$1.21 - $1.32+1.56%Beat+9.2%143 up, 0 downJan 20, 2022$1.55B
    Sep 30, 2021$1.19$1.16$1.07 - $1.29+2.59%Beat+29.3%15N/AOct 19, 2021$1.40B
    Jun 30, 2021$1.31$1.02$0.92 - $1.17+28.43%Beat+254.1%15N/AJul 20, 2021$1.46B
    Mar 31, 2021$1.17$0.88$0.77 - $0.94+32.95%Beat+30.0%15N/AApr 20, 2021$1.29B
    Dec 31, 2020$1.19$1.04$0.97 - $1.13+14.42%Beat+2.6%15N/AJan 21, 2021$1.33B
    Sep 30, 2020$0.92$0.68$0.57 - $0.78+35.29%Beat-19.3%15N/AOct 15, 2020$1.08B
    Jun 30, 2020$0.37$0.16-$0.02 - $1.86+131.25%Beat-65.7%12N/AJul 21, 2020$852.10M
    Mar 31, 2020$0.90$0.85$0.66 - $1.02+5.88%Beat+3.4%9N/AApr 16, 2020$1.10B
    Dec 31, 2019$1.16$1.13$1.03 - $1.23+2.65%Beat+17.2%14N/AJan 23, 2020$1.28B
    Sep 30, 2019$1.14$1.00$0.94 - $1.03+14.00%Beat+21.3%15N/AOct 17, 2019$1.13B
    Jun 30, 2019$1.08$0.96$0.89 - $1.02+12.50%Beat+17.4%16N/AJul 18, 2019$1.10B
    Mar 31, 2019$0.87$0.90$0.86 - $0.94-3.33%Miss+7.4%15N/AApr 18, 2019$973.70M
    Dec 31, 2018$0.99$1.02$0.97 - $1.16-2.94%Miss+16.5%15N/AJan 24, 2019$1.05B
    Sep 30, 2018$0.94$0.89$0.83 - $0.96+5.62%Beat+2.2%15N/AOct 18, 2018$920.90M
    Jun 30, 2018$0.92$0.83$0.78 - $0.86+10.84%Beat+39.4%13N/AJul 19, 2018$909.30M
    Mar 31, 2018$0.81$0.69$0.66 - $0.76+17.39%Beat+42.1%14N/AApr 17, 2018$847.50M
    Dec 31, 2017$0.85$0.76$0.72 - $0.80+11.84%Beat+25.0%13N/AJan 25, 2018$892.00M
    Sep 30, 2017$0.92$0.66$0.63 - $0.71+39.39%Beat+33.3%15N/AOct 19, 2017$807.80M
    Jun 30, 2017$0.66$0.64$0.61 - $0.67+3.13%Beat+6.5%16N/AJul 20, 2017$758.80M
    Mar 31, 2017$0.57$0.55N/A+3.64%Beat+16.3%N/AN/AApr 18, 2017$679.60M
    Dec 31, 2016$0.68$0.67N/A+1.49%Beat+4.6%N/AN/AJan 24, 2017$759.00M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $8.93, up 21.8% from the year before. It was $2.48 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$8.93+21.8%
    Dec 31, 2024$7.33+28.4%
    Dec 31, 2023$5.71+21.7%
    Dec 31, 2022$4.69-5.6%
    Dec 31, 2021$4.97+47.0%
    Dec 31, 2020$3.38-20.5%
    Dec 31, 2019$4.25+16.1%
    Dec 31, 2018$3.66+22.0%
    Dec 31, 2017$3.00+21.0%
    Dec 31, 2016$2.48N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,400 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,35214
    2026Q2Jun 30, 20267,84313
    2026Q1Mar 31, 20267,1049
    2025Q4Dec 31, 20257,78210
    2025Q3Sep 30, 20258,71711
    2025Q2Jun 30, 20257,67710
    2025Q1Mar 31, 20252,40010
    2024Q4Dec 31, 20248,28911

    2026Q3 Earnings Call

    Opening remarks

    Daniel Connally Head of Investor Relations Good afternoon, and welcome to Intuitive's Q3 2026 Earnings Conference Call. Joining me today are Dave Rosa, our CEO; Jamie Samath, our CFO; Dr. Jaime Wong, our Chief Medical Officer; and Gary Loeb, our Chief Legal and Compliance Officer. Before we begin, I would like to remind you that comments made on today's call may contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in our Securities and Exchange Commission filings, including our most recent 10-K filed on February 3, 2026, and 10-Q filed on July 21, 2026. Our SEC filings can be found through our website at intuitive.com or at the SEC's website. Investors are cautioned not to place undue reliance on such forward-looking statements. This conference call will be available for audio replay on our website in the Events section under our Investor Relations page. We have posted today's press release and supplementary financial data tables to our website. Our format for this afternoon's conference call is as follows: Dave will review our business and operational highlights, Jamie will review our financial results and procedure highlights, Jaime Wong will review clinical highlights, I will review our updated financial outlook for 2026, and finally, we will host a question-and-answer session. With that, I will turn it over to Dave.

    David Rosa CEO Good afternoon, and thank you for joining us today. Q3 was a strong quarter for Intuitive with broad-based adoption across our multiport, single-port and Ion platforms. In Q3, total procedures increased 15%, driven by 14% growth in da Vinci procedures and 31% growth in Ion procedures. In the U.S., da Vinci procedure growth was 10%, and outside the U.S., da Vinci procedure growth was 20%. We exited the quarter with more than 13,200 da Vinci and Ion systems installed worldwide. Over time, our customers have adopted, operationalized and standardized on the da Vinci ecosystem to provide their patients with improved care. That adoption has been driven by our commitment to innovation, robust training and clinical evidence, and it is apparent in how customers use da Vinci today. In the quarter, almost 7,000 customers in more than 70 countries performed da Vinci procedures at a rate of over 10,000 procedures per day. On the clinical evidence front, more than 48,000 peer-reviewed publications have evaluated the effectiveness of da Vinci surgery, including the recent benign COMPARE study, which Jaime Wong will discuss in more detail shortly. As I described last quarter, we continue to see increasing segmentation across our customer base. Needs vary by procedure, site of care, geography and health care system.

    Frequently Asked Questions About ISRG

    When is Intuitive Surgical's next earnings date?

    Intuitive Surgical's next earnings report is expected for Jan 20, 2027.

    Did ISRG beat earnings estimates last quarter?

    Yes. Intuitive Surgical reported EPS of $3.00 for the quarter ended Sep 30, 2026, above the $2.13 estimate, a 40.85% surprise.

    What EPS do analysts expect from ISRG next quarter?

    The consensus EPS estimate for Intuitive Surgical for the quarter ending Dec 31, 2026 is $3.01 from 30 analysts, with estimates from $2.79 to $3.19.

    How often does ISRG beat earnings estimates?

    Intuitive Surgical beat the EPS estimate in each of the last 15 quarters, with an average surprise of +15.00%.